title: Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
abstract: BACKGROUND
  In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk.
  
  
  METHODS
  In pilot studies conducted with RV144 blood samples, 17 antibody or cellular assays met prespecified criteria, of which 6 were chosen for primary analysis to determine the roles of T-cell, IgG antibody, and IgA antibody responses in the modulation of infection risk. Assays were performed on samples from 41 vaccinees who became infected and 205 uninfected vaccinees, obtained 2 weeks after final immunization, to evaluate whether immune-response variables predicted HIV-1 infection through 42 months of follow-up.
  
  
  RESULTS
  Of six primary variables, two correlated significantly with infection risk: the binding of IgG antibodies to variable regions 1 and 2 (V1V2) of HIV-1 envelope proteins (Env) correlated inversely with the rate of HIV-1 infection (estimated odds ratio, 0.57 per 1-SD increase; P=0.02; q=0.08), and the binding of plasma IgA antibodies to Env correlated directly with the rate of infection (estimated odds ratio, 1.54 per 1-SD increase; P=0.03; q=0.08). Neither low levels of V1V2 antibodies nor high levels of Env-specific IgA antibodies were associated with higher rates of infection than were found in the placebo group. Secondary analyses suggested that Env-specific IgA antibodies may mitigate the effects of potentially protective antibodies.
  
  
  CONCLUSIONS
  This immune-correlates study generated the hypotheses that V1V2 antibodies may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies may have mitigated the effects of protective antibodies. Vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
authors.affiliation: Duke University Human Vaccine Institute and the Center for HIV/AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA. hayne002@mc.duke.edu
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.forename: Peter B
authors.initials: PB
authors.lastname: Gilbert
authors.forename: M Juliana
authors.initials: MJ
authors.lastname: McElrath
authors.forename: Susan
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: Georgia D
authors.initials: GD
authors.lastname: Tomaras
authors.forename: S Munir
authors.initials: SM
authors.lastname: Alam
authors.forename: David T
authors.initials: DT
authors.lastname: Evans
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: Chitraporn
authors.initials: C
authors.lastname: Karnasuta
authors.forename: Ruengpueng
authors.initials: R
authors.lastname: Sutthent
authors.forename: Hua-Xin
authors.initials: HX
authors.lastname: Liao
authors.forename: Anthony L
authors.initials: AL
authors.lastname: DeVico
authors.forename: George K
authors.initials: GK
authors.lastname: Lewis
authors.forename: Constance
authors.initials: C
authors.lastname: Williams
authors.forename: Abraham
authors.initials: A
authors.lastname: Pinter
authors.forename: Youyi
authors.initials: Y
authors.lastname: Fong
authors.forename: Holly
authors.initials: H
authors.lastname: Janes
authors.forename: Allan
authors.initials: A
authors.lastname: DeCamp
authors.forename: Yunda
authors.initials: Y
authors.lastname: Huang
authors.forename: Mangala
authors.initials: M
authors.lastname: Rao
authors.forename: Erik
authors.initials: E
authors.lastname: Billings
authors.forename: Nicos
authors.initials: N
authors.lastname: Karasavvas
authors.forename: Merlin L
authors.initials: ML
authors.lastname: Robb
authors.forename: Viseth
authors.initials: V
authors.lastname: Ngauy
authors.forename: Mark S
authors.initials: MS
authors.lastname: de Souza
authors.forename: Robert
authors.initials: R
authors.lastname: Paris
authors.forename: Guido
authors.initials: G
authors.lastname: Ferrari
authors.forename: Robert T
authors.initials: RT
authors.lastname: Bailer
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Soderberg
authors.forename: Charla
authors.initials: C
authors.lastname: Andrews
authors.forename: Phillip W
authors.initials: PW
authors.lastname: Berman
authors.forename: Nicole
authors.initials: N
authors.lastname: Frahm
authors.forename: Stephen C
authors.initials: SC
authors.lastname: De Rosa
authors.forename: Michael D
authors.initials: MD
authors.lastname: Alpert
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Yates
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Shen
authors.forename: Richard A
authors.initials: RA
authors.lastname: Koup
authors.forename: Punnee
authors.initials: P
authors.lastname: Pitisuttithum
authors.forename: Jaranit
authors.initials: J
authors.lastname: Kaewkungwal
authors.forename: Sorachai
authors.initials: S
authors.lastname: Nitayaphan
authors.forename: Supachai
authors.initials: S
authors.lastname: Rerks-Ngarm
authors.forename: Nelson L
authors.initials: NL
authors.lastname: Michael
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Kim
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000328:Adult; D016022:Case-Control Studies; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D015999:Multivariate Analysis; D016017:Odds Ratio; D012044:Regression Analysis; D012306:Risk; D016896:Treatment Outcome
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D007070:Immunoglobulin A